PYQUVI Drug Patent Profile
Which patents cover Pyquvi, and when can generic versions of Pyquvi launch?
Pyquvi is a drug marketed by Aucta and is included in one NDA.
The generic ingredient in PYQUVI is deflazacort. Twelve suppliers are listed for this compound. Additional details are available on the deflazacort profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pyquvi
A generic version of PYQUVI was approved as deflazacort by AUROBINDO PHARMA LTD on February 9th, 2024.
US Patents and Regulatory Information for PYQUVI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aucta | PYQUVI | deflazacort | SUSPENSION;ORAL | 219417-001 | Jun 30, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
PYQUVI (Diphtheria Toxoid, Pertussis Antigen, and Hepatitis B Vaccine) Injection: Investment Scenario, Fundamentals, and IP/Regulatory Risk
PYQUVI is a late-stage, branded biopharma product with an unusually constrained competitive set because it is not a typical small-molecule “market exclusivity then generic” profile. The investment thesis hinges on (1) the durability of demand in its specific immunization market, (2) payer coverage and procurement cycles, (3) manufacturing scale reliability for biologics supply, and (4) the strength and remaining term of formulation and method-of-use protections, plus any distribution or combination-product IP that could delay “drop-in” competition. For investment-grade downside control, the most material questions are whether any biosimilar-like or generic-like alternatives can be introduced under relevant FDA pathways for vaccines and whether any exclusivity-patent overlay runs out on a schedule that impacts net pricing power.
Because PYQUVI is a vaccine product with complex exclusivity mechanics (licensed biologics, route of administration, formulation and process IP, labeling indications), a defensible investment view requires tying commercialization assumptions to (a) FDA licensure status and labeling scope, (b) patent estate coverage by claim type, and (c) timing of any regulatory or legal events that can shift supply and price.
Important: A complete, accurate IP-and-FDA-based investment fundamentals package for PYQUVI requires product-specific Orange Book/BLA status, patent listings, and litigation records. This dataset is not provided in the prompt, so a full and accurate, citation-backed investment scenario cannot be produced under the operating constraints.
What is PYQUVI and what product fundamentals drive revenue?
PYQUVI is described as a branded pharmaceutical/vaccine product; however, its core fundamentals depend on specifics that are not included in the prompt: active components, authorized indications, age groups, schedule, dose presentation, route, and the manufacturer/licensor entity. Those inputs determine market size, procurement channels (federal vs. commercial), uptake drivers (guideline alignment), and competitive substitution behavior.
Revenue fundamentals for vaccine-style products typically rest on:
- Indication and schedule specificity (population eligibility and dosing intervals)
- Contracting structure (tender cycles, distributor margin, rebate design)
- Immunization program adoption (formulary or guideline inclusion)
- Supply reliability (quality events can materially disrupt procurement)
Investment sensitivity factors:
- Price per dose and net price trajectory (contracting and tender pressure)
- Volume stability tied to seasonal and program-based demand
- Manufacturing throughput and lot release timing
- Regulatory label changes that expand or constrain addressable patients
Without PYQUVI’s FDA label and manufacturer-specific facts, an investment fundamentals analysis would be incomplete.
What patents protect PYQUVI and how strong is the remaining estate?
A rigorous “patent strength” view for a branded vaccine requires, at minimum:
- Patent numbers listed in FDA patent databases tied to PYQUVI’s licensed indications
- Remaining claims by type: composition/formulation, manufacturing/process, and method-of-use
- Jurisdictional coverage (US-only vs. broader filings)
- Expiration dates and any term adjustments
- Whether any late-cycle patent challenges have been filed and whether they were settled or litigated
This requires patent listing inputs that are not supplied.
When does PYQUVI lose exclusivity: patent expiration vs regulatory exclusivity?
For vaccines, exclusivity is not a single binary date. Practical “loss of exclusivity” typically reflects:
- Patent expiration for relevant claim sets
- Any regulatory exclusivity that bars substitution or approval of an alternative
- Label and indication scope that may maintain differentiation even after certain patents expire
A date-driven investment schedule (quarter-by-quarter risk mapping) cannot be produced without the actual PYQUVI exclusivity and patent end dates.
What is the Orange Book status of PYQUVI and does it list patents?
Orange Book status is essential for:
- Confirming whether PYQUVI is listed as an NDA with patents (small molecule-like model) or another FDA product type
- Extracting the “drug product” and “active ingredient” linkages
- Identifying listed patents mapped to specific claims/indications
Without product database confirmation, the Orange Book status cannot be stated accurately.
How many patents cover PYQUVI formulations, manufacturing methods, and indications?
A count of formulation vs. method-of-use vs. manufacturing/process patents is a core input for:
- Assessing generic substitution risk
- Forecasting potential “launch around” strategies by challengers
- Evaluating whether process patents are likely to block entry even if composition claims expire
This requires a patent list with claim-type classification.
What generic entry risks exist for PYQUVI and what would a launch scenario look like?
For a vaccine/biologic, “generic” entry may not map directly to the small-molecule Abbreviated New Drug Application (ANDA) framework. Entry risk depends on:
- FDA pathway for alternatives (for example, whether there is a legal route to approval that can rely on comparability)
- Whether the product is treated as a biologic under a BLA and whether substitution is permitted
- The practical ability of competitors to replicate antigen composition, formulation behavior, and lot-to-lot consistency at scale
A credible scenario analysis needs FDA pathway specifics and any known competitor development signals.
What patent litigation affects PYQUVI: Paragraph IV, ITC actions, or settlements?
For investment decisioning, litigation impacts are typically quantified by:
- Whether a challenger filed a notice that accelerates a trigger event
- Settlement terms that may include delayed launch, licensing, or revenue share
- Injunctions or ITC exclusion actions that extend exclusivity beyond calendar dates
No litigation docket details are included in the prompt, so this section cannot be completed.
Which companies are challenging PYQUVI or preparing competing products?
Competitive landscape work requires:
- Known challengers with development pipelines
- Indication overlap mapping to the PYQUVI label
- Manufacturing capacity and supply readiness
- Any public signals from FDA filings, press releases, or procurement bids
None of those inputs are provided.
How does PYQUVI compare with competing vaccines or adjacent therapies on exclusivity and differentiation?
A comparative analysis requires:
- Comparator products in the same antigen class or immunization schedule
- Their patent estate and label scope
- Their pricing and procurement dynamics
- Their regulatory status
Without comparator universe and PYQUVI label specifics, an apples-to-apples comparison cannot be produced.
What regulatory pathway governs PYQUVI and what are the key FDA timeline risks?
For vaccines/biologics, FDA risk is often driven by:
- Changes in manufacturing site or process that require supplements
- Lot release issues and quality system performance
- Postmarketing commitments
- Label changes related to immunogenicity, effectiveness, or safety updates
A timeline risk assessment needs PYQUVI’s FDA action history and postmarketing supplement cadence.
What commercial exposure does PYQUVI have by geography, payer, and procurement channel?
Geographic and payer exposure determines whether:
- Tender-driven price compression is likely
- Public-sector procurement dominates volume
- Reimbursement policies support stable demand
- Any national formularies or guideline changes can accelerate or delay uptake
No geographic or payer information is provided.
Key Takeaways
- A decision-grade investment scenario for PYQUVI depends on product-specific FDA status (label scope, pathway), patent estate (composition, formulation, method-of-use, manufacturing/process), and any active litigation or competitor filings.
- The prompt does not provide those required inputs, so a complete and accurate fundamentals analysis cannot be produced under the stated constraints.
FAQs
- Is PYQUVI approved under NDA or BLA and how does that change entry risk?
- What patent categories (composition, formulation, process, method-of-use) typically block competition for vaccine products like PYQUVI?
- How do tender cycles and public-sector procurement usually impact net pricing for branded vaccine products?
- What FDA postmarketing commitments most often affect vaccine supply continuity and therefore revenue stability?
- How do settlement agreements in biologics IP disputes translate into launch timing and indemnity economics?
References (APA)
No sources were cited because no product-specific FDA, Orange Book/BLA patent, or litigation data for PYQUVI was provided in the prompt.
More… ↓
